Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines

Simple item page
dc.article.number1259
dc.catalogadorpva
dc.contributor.authorXanthippi Topalidou
dc.contributor.authorAlexis Kalergis
dc.contributor.authorGeorgios Papazisis
dc.date.accessioned2024-03-04T15:19:38Z
dc.date.available2024-03-04T15:19:38Z
dc.date.issued2023
dc.description.abstractRespiratory syncytial virus (RSV) is responsible for a significant proportion of global morbidity and mortality affecting young children and older adults. In the aftermath of formalin-inactivated RSV vaccine development, the effort to develop an immunizing agent was carefully guided by epidemiologic and pathophysiological evidence of the virus, including various vaccine technologies. The pipeline of RSV vaccine development includes messenger ribonucleic acid (mRNA), live-attenuated (LAV), subunit, and recombinant vector-based vaccine candidates targeting different virus proteins. The availability of vaccine candidates of various technologies enables adjustment to the individualized needs of each vulnerable age group. Arexvy® (GSK), followed by Abrysvo® (Pfizer), is the first vaccine available for market use as an immunizing agent to prevent lower respiratory tract disease in older adults. Abrysvo is additionally indicated for the passive immunization of infants by maternal administration during pregnancy. This review presents the RSV vaccine pipeline, analyzing the results of clinical trials. The key features of each vaccine technology are also mentioned. Currently, 24 vaccines are in the clinical stage of development, including the 2 licensed vaccines. Research in the field of RSV vaccination, including the pharmacovigilance methods of already approved vaccines, promotes the achievement of successful prevention.
dc.fechaingreso.objetodigital2024-05-27
dc.format.extent37 páginas
dc.fuente.origenORCID
dc.identifier.doi10.3390/pathogens12101259
dc.identifier.eissn2076-0817
dc.identifier.urihttps://doi.org/10.3390/pathogens12101259
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/82442
dc.information.autorucEscuela de Medicina; Kalergis Parra, Alexis Mikes; 0000-0001-7622-5263; 90610
dc.issue.numero10
dc.language.isoen
dc.nota.accesoContenido completo
dc.pagina.final37
dc.pagina.inicio1
dc.revistaPathogens
dc.rightsacceso abierto
dc.rights.licenseCC BY 4.0 DEED Attribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectRespiratory syncytial virus (RSV)
dc.subjectVaccine development
dc.subjectPrevention
dc.subjectLower respiratory tract infection (LRTI)
dc.subjectVaccine candidates
dc.subjectSubunit vaccine
dc.subjectLive-attenuated vaccine
dc.subjectmRNA vaccine
dc.subjectRecombinant vaccine
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titleRespiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines
dc.typeartículo
dc.volumen12
sipa.codpersvinculados90610
sipa.trazabilidadORCID;2024-01-15
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
pathogens-12-01259-v2 Respiratory Syncytial Virus Vaccines.pdf
Size:
1.25 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas